Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
75
×
life sciences
national
75
×
national blog main
national top stories
boston blog main
boston top stories
san francisco top stories
san francisco blog main
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
texas top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
seattle blog main
seattle top stories
texas blog main
wisconsin blog main
wisconsin top stories
indiana blog main
indiana top stories
fda
clinical trials
cancer
novartis
pfizer
bristol-myers squibb
cancer immunotherapy
merck
eli lilly
startups
amgen
deals
medicare
What
roundup
bio
drug
life
medical
new
medicine
cancer
sciences
fda
week
drugs
health
ipo
xcelerating
breakthroughs
companies
digital
future
science
accelerating
attend
biopharma's
biopharma’s
biotech
boston
conference
join
learn
medicines
plan
registering
team
tech
annual
days
patients
prices
approval
ceo
Language
unset
unknown
Current search:
national
×
biotech
×
@xconomy.com
5 years ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More
@xconomy.com
5 years ago
Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com
5 years ago
Ireland to Sequence 400K Genomes With New Precision Medicine Effort
@xconomy.com
5 years ago
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More
@xconomy.com
5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
5 years ago
Trump Plan Ties Medicare Drug Prices to Cheaper Foreign Ones
@xconomy.com
5 years ago
ESMO ’18: Precision Meds, Breast, Lung, and More from the Cancer Front
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
Nobel Medicine Prize Honors Cancer Immunotherapy Pioneers Allison & Honjo
@xconomy.com
5 years ago
Six Life Science Firms Close Q3 with an IPO, More Are on the Way
@xconomy.com
5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M
@xconomy.com
5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines
@xconomy.com
6 years ago
Trump Pledges Lower Drug Prices, But Blueprint Is Short on Details
@xconomy.com
6 years ago
Will New Study Cut Guesswork for Depression Medicine Prescriptions?
First
Prev
Page 2
(current)
Next
Last